Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
e-STOP 2 early antibiotic discontinuation in high-risk pediatric febrile neutropenia
2025-524264-38-00Phase 4Authorised
- Sponsor
- Vall d'Hebron Research Institute
- Start
- May 2026
- Modality
- Antimicrobial Peptides → Native Peptides → Peptides, Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of cefepime, teicoplanin, metronidazole, meropenem, tazobactam and 6 more in febrile neutropenia (FN) (2 arms), sponsored by Vall d'Hebron Research Institute. Primary endpoint: Uncomplicated resolution at 28 days. Planned start May 2026; status: authorised.
02
Drugs
cefepimeteicoplaninmetronidazolemeropenemtazobactam
03
Conditions
febrile neutropenia (FN)
Beyond the preview
Go deeper on 2025-524264-38-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524264-38-00.